Bioray Laboratories
Clinical trials sponsored by Bioray Laboratories, explained in plain language.
-
Off-the-shelf CAR-T therapy tested for hard-to-treat lymphoma
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy that is made from donor cells (universal) and targets CD19 on cancer cells. It is for people with relapsed or refractory B-cell non-Hodgkin lymphoma. Up to 6 adults will receive the treatment to check safety and side effects.
Phase: NA • Sponsor: Bioray Laboratories • Aim: Disease control
Last updated May 26, 2026 08:19 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancer
Disease control Recruiting nowThis early study tests a new treatment called BCMA-UCART, which uses donor immune cells engineered to find and attack a protein (BCMA) on multiple myeloma cells. It is for adults whose cancer has returned or not responded to at least two prior treatments. The main goals are to ch…
Phase: NA • Sponsor: Bioray Laboratories • Aim: Disease control
Last updated May 26, 2026 08:12 UTC
-
Engineered immune cells take on tough lymphoma in early trial
Disease control Recruiting nowThis study tests a new treatment called BRL-201 for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better find and attack c…
Phase: PHASE1 • Sponsor: Bioray Laboratories • Aim: Disease control
Last updated May 18, 2026 12:05 UTC